152 related articles for article (PubMed ID: 36634455)
1. Structure-based development of potent Plasmodium falciparum M1 and M17 aminopeptidase selective and dual inhibitors via S1'-region optimisation.
Calic PPS; Vinh NB; Webb CT; Malcolm TR; Ngo A; Lowes K; Drinkwater N; McGowan S; Scammells PJ
Eur J Med Chem; 2023 Feb; 248():115051. PubMed ID: 36634455
[TBL] [Abstract][Full Text] [Related]
2. Potent dual inhibitors of Plasmodium falciparum M1 and M17 aminopeptidases through optimization of S1 pocket interactions.
Drinkwater N; Vinh NB; Mistry SN; Bamert RS; Ruggeri C; Holleran JP; Loganathan S; Paiardini A; Charman SA; Powell AK; Avery VM; McGowan S; Scammells PJ
Eur J Med Chem; 2016 Mar; 110():43-64. PubMed ID: 26807544
[TBL] [Abstract][Full Text] [Related]
3. X-ray crystal structures of an orally available aminopeptidase inhibitor, Tosedostat, bound to anti-malarial drug targets PfA-M1 and PfA-M17.
Drinkwater N; Bamert RS; Sivaraman KK; Paiardini A; McGowan S
Proteins; 2015 Apr; 83(4):789-95. PubMed ID: 25645579
[TBL] [Abstract][Full Text] [Related]
4. Screening the Medicines for Malaria Venture "Malaria Box" against the Plasmodium falciparum aminopeptidases, M1, M17 and M18.
Paiardini A; Bamert RS; Kannan-Sivaraman K; Drinkwater N; Mistry SN; Scammells PJ; McGowan S
PLoS One; 2015; 10(2):e0115859. PubMed ID: 25700165
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of PfA-M1, over PfA-M17, by an amino-benzosuberone derivative blocks malaria parasites development in vitro and in vivo.
Bounaadja L; Schmitt M; Albrecht S; Mouray E; Tarnus C; Florent I
Malar J; 2017 Sep; 16(1):382. PubMed ID: 28934959
[TBL] [Abstract][Full Text] [Related]
6. Genetic and chemical validation of
Edgar RCS; Siddiqui G; Hjerrild K; Malcolm TR; Vinh NB; Webb CT; Holmes C; MacRaild CA; Chernih HC; Suen WW; Counihan NA; Creek DJ; Scammells PJ; McGowan S; de Koning-Ward TF
Elife; 2022 Sep; 11():. PubMed ID: 36097817
[TBL] [Abstract][Full Text] [Related]
7. Two-pronged attack: dual inhibition of Plasmodium falciparum M1 and M17 metalloaminopeptidases by a novel series of hydroxamic acid-based inhibitors.
Mistry SN; Drinkwater N; Ruggeri C; Sivaraman KK; Loganathan S; Fletcher S; Drag M; Paiardini A; Avery VM; Scammells PJ; McGowan S
J Med Chem; 2014 Nov; 57(21):9168-83. PubMed ID: 25299353
[TBL] [Abstract][Full Text] [Related]
8. Structure of the Plasmodium falciparum M17 aminopeptidase and significance for the design of drugs targeting the neutral exopeptidases.
McGowan S; Oellig CA; Birru WA; Caradoc-Davies TT; Stack CM; Lowther J; Skinner-Adams T; Mucha A; Kafarski P; Grembecka J; Trenholme KR; Buckle AM; Gardiner DL; Dalton JP; Whisstock JC
Proc Natl Acad Sci U S A; 2010 Feb; 107(6):2449-54. PubMed ID: 20133789
[TBL] [Abstract][Full Text] [Related]
9. Identification and Validation of a Potent Dual Inhibitor of the P. falciparum M1 and M17 Aminopeptidases Using Virtual Screening.
Ruggeri C; Drinkwater N; Sivaraman KK; Bamert RS; McGowan S; Paiardini A
PLoS One; 2015; 10(9):e0138957. PubMed ID: 26406322
[TBL] [Abstract][Full Text] [Related]
10. Hydroxamic Acid Inhibitors Provide Cross-Species Inhibition of Plasmodium M1 and M17 Aminopeptidases.
Vinh NB; Drinkwater N; Malcolm TR; Kassiou M; Lucantoni L; Grin PM; Butler GS; Duffy S; Overall CM; Avery VM; Scammells PJ; McGowan S
J Med Chem; 2019 Jan; 62(2):622-640. PubMed ID: 30537832
[TBL] [Abstract][Full Text] [Related]
11. Screening and In Vitro Evaluation of Potential Plasmodium falciparum Leucyl Aminopeptidase Inhibitors.
Chaudhary M; Singh V; Anvikar AR; Sahi S
Curr Comput Aided Drug Des; 2016; 12(4):282-293. PubMed ID: 27449897
[TBL] [Abstract][Full Text] [Related]
12. KBE009: An antimalarial bestatin-like inhibitor of the Plasmodium falciparum M1 aminopeptidase discovered in an Ugi multicomponent reaction-derived peptidomimetic library.
González-Bacerio J; Maluf SEC; Méndez Y; Pascual I; Florent I; Melo PMS; Budu A; Ferreira JC; Moreno E; Carmona AK; Rivera DG; Alonso Del Rivero M; Gazarini ML
Bioorg Med Chem; 2017 Sep; 25(17):4628-4636. PubMed ID: 28728898
[TBL] [Abstract][Full Text] [Related]
13. Modelling of human leucyl aminopeptidases for in silico off target binding analysis of potential Plasmodium falciparum leucine aminopeptidase (PfA-M17) specific inhibitors.
Sahi S; Raj U; Chaudhary M; Nain V
Recent Pat Endocr Metab Immune Drug Discov; 2014; 8(3):191-201. PubMed ID: 25269653
[TBL] [Abstract][Full Text] [Related]
14. On-target, dual aminopeptidase inhibition provides cross-species antimalarial activity.
Edgar RCS; Malcolm TR; Siddiqui G; Giannangelo C; Counihan NA; Challis M; Duffy S; Chowdhury M; Marfurt J; Dans M; Wirjanata G; Noviyanti R; Daware K; Suraweera CD; Price RN; Wittlin S; Avery VM; Drinkwater N; Charman SA; Creek DJ; de Koning-Ward TF; Scammells PJ; McGowan S
mBio; 2024 Jun; 15(6):e0096624. PubMed ID: 38717141
[TBL] [Abstract][Full Text] [Related]
15. Mapping the Pathway and Dynamics of Bestatin Inhibition of the Plasmodium falciparum M1 Aminopeptidase PfA-M1.
Yang W; Riley BT; Lei X; Porebski BT; Kass I; Buckle AM; McGowan S
ChemMedChem; 2018 Dec; 13(23):2504-2513. PubMed ID: 30318749
[TBL] [Abstract][Full Text] [Related]
16. Engagement of the S1, S1' and S2' subsites drives efficient catalysis of peptide bond hydrolysis by the M1-family aminopeptidase from Plasmodium falciparum.
Dalal S; Ragheb DR; Klemba M
Mol Biochem Parasitol; 2012 May; 183(1):70-7. PubMed ID: 22348949
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and structure-activity relationships of phosphonic arginine mimetics as inhibitors of the M1 and M17 aminopeptidases from Plasmodium falciparum.
Kannan Sivaraman K; Paiardini A; Sieńczyk M; Ruggeri C; Oellig CA; Dalton JP; Scammells PJ; Drag M; McGowan S
J Med Chem; 2013 Jun; 56(12):5213-7. PubMed ID: 23713488
[TBL] [Abstract][Full Text] [Related]
18. Novel selective inhibitors of the zinc plasmodial aminopeptidase PfA-M1 as potential antimalarial agents.
Flipo M; Beghyn T; Leroux V; Florent I; Deprez BP; Deprez-Poulain RF
J Med Chem; 2007 Mar; 50(6):1322-34. PubMed ID: 17326615
[TBL] [Abstract][Full Text] [Related]
19. Active site metals mediate an oligomeric equilibrium in Plasmodium M17 aminopeptidases.
Malcolm TR; Belousoff MJ; Venugopal H; Borg NA; Drinkwater N; Atkinson SC; McGowan S
J Biol Chem; 2021; 296():100173. PubMed ID: 33303633
[TBL] [Abstract][Full Text] [Related]
20. Mapping the substrate specificity of the Plasmodium M1 and M17 aminopeptidases.
Malcolm TR; Swiderska KW; Hayes BK; Webb CT; Drag M; Drinkwater N; McGowan S
Biochem J; 2021 Jul; 478(13):2697-2713. PubMed ID: 34133730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
